Pfizer beats forecasts as oncology drugs grow

July 29 (Reuters) - Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.